

1 August 2018

NSX Announcement

## **EXTENSION OF EXCLUSIVITY PERIOD WITH CYSTEMIX**

Beroni Group Limited (NSX: BTG) (“Beroni Group” or the “Company”) advises that it has entered into a deed with NewSouth Innovations Pty Ltd (“NSI”), a subsidiary of the University of New South Wales (“UNSW”) and Cystemix Pty Limited (“Cystemix”), to extend the term of the term sheet (entered into between the parties on 28 March 2018) to 30 September 2018. The extension was required due to delays in obtaining advice on R&D arrangements within Cystemix. Other than the extension of the term, the terms of the term sheet remain unchanged.

Beroni intends to invest in Cystemix to advance Cystemix’s clinical development of the potentially groundbreaking anti-cancer drug called PENAO. Subject to the execution of a Share Subscription and Shareholders Agreement (“Transaction Documents”) by the parties, it is intended that Beroni will invest \$10 million (including the \$400,000 under the term sheet) through tranches for 40% shares (including the 2.2% shares under the term sheet) in Cystemix by the end of Phase II clinical trial of PENAO. NSI would hold the remaining 60% shares in Cystemix. Subsequent investment tranches, together with the milestones associated with the Phase II Clinical Trials of PENAO, will be finalised and form part of the Transaction Documents. It is also intended that the Transaction Documents will include a right for Beroni to acquire a further 11% shares in Cystemix during the period commencing when 50% patient enrolment of a Phase II trial and ending within 2 months after Phase II trial completion date for \$5,500,000.

Beroni will announce material information of the Transaction Documents when they are finalised.

For further information please contact:

Mr Jacky Zhang  
Executive Chairman  
Tel: +86 1851 6931 911  
E: [1710426553@qq.com](mailto:1710426553@qq.com)

Mr Peter Wong  
Executive Director & CFO  
Tel: +61 423 727 580  
E: [pwong@asiainvest.com.au](mailto:pwong@asiainvest.com.au)

### **About Beroni Group Limited (NSX:BTG) (FSE:6B9)**

Beroni Group is a biotechnological company which is dual listed on the National Stock Exchange (Australia) and Frankfurt Stock Exchange. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects. Beroni Group’s overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries.